Growth and change of COVID-19 until 2030

The major players in the non-invasive prenatal testing market are F. Hoffmann-La Roche AG, Illumina, Inc., Laboratory Corporation of America Holdings, Natera, Inc. and PerkinElmer Inc. The global non-invasive prenatal testing market is expected to grow from of $ 2.

New York, September 28, 2021 (GLOBE NEWSWIRE) – announces the publication of the report “Global Non-Invasive Prenatal Testing Market Report 2021: COVID-19 Growth And Change To 2030” – https: // www.
$ 17 billion in 2020 to $ 2.43 billion in 2021 at a compound annual growth rate (CAGR) of 12%. The growth is mainly due to companies resuming operations and adjusting to the new normal while recovering from the impact of COVID-19, which previously led to restrictive containment measures involving social distancing, the remote work and closure of business activities which resulted in operational challenges. The market is expected to reach $ 4.02 billion in 2025 at a CAGR of 13.4%.

The non-invasive prenatal testing market includes the sale of non-invasive prenatal testing kits, related instruments and services. Non-invasive prenatal testing kits and equipment are used to diagnose genetic abnormalities, primarily chromosomal abnormalities in the fetus during the first trimester of pregnancy.

Non-invasive prenatal testing includes ultrasound detection, fetal cells in maternal blood tests, cell-free DNA in maternal plasma tests, and biochemical screening tests.

The non-invasive prenatal testing market covered in this report is segmented by type into consumables and instruments. It is also segmented by end user into hospitals and diagnostic laboratories; by instruments in NGS systems, PCR instruments, DNA chips, ultrasound devices, others (centrifuges, UV systems, incubators, microscopes); by consumables in assay kits and reagents, disposables and by application in Down’s syndrome, microdeletion, genetics, Rh factor.

The regions covered in this report are Asia Pacific, Western Europe, Eastern Europe, North America, South America, Middle East & Africa.

Ethical hurdles in the non-invasive prenatal testing (NPNI) market have led to a series of ethical issues in terms of sex selection or abortion of babies with a chromosomal abnormality. Determining the sex of the fetus or whether the baby has an abnormality at an earlier stage has led to abortions and resulted in an ethical problem which has further led to strict regulations on the use of such devices.

According to the Department of Health (UK), there have been 3,213 abortions in England and Wales, of which 37% of total abortions were chromosomal abnormalities and 80% of abortions were performed before 10 weeks of age. pregnancy. These barriers will restrict the market for non-invasive prenatal testing.

Next-generation sequencing has increased throughput, scalability and speed, further enabling researchers to perform a wide range of applications and study biological systems at a higher level. Next Generation Sequencing is a platform that has enabled the sequencing of thousands to millions of DNA molecules simultaneously.

Manufacturers have introduced this technology to reduce the time and money required and optimize the yield to generate results regarding genome, DNA testing. Large companies such as Illumina, Eurofins, Natera, Roche and Annoroad have implemented this technology in non-invasive prenatal testing. .

The CFDA (China Food and Drug Administration) has approved the registration of the medical device product of the NGS NextSeq 550AR instrument produced by Annoroad.

In June 2019, Invitae, a US-based medical genetics company, acquired Singular Bio for $ 55 million. This acquisition will further strengthen Invitae’s ability to integrate genetic information into traditional medical care.

Singular Bio, a US-based company specializing in single-molecule cell-free DNA analysis that it develops for non-invasive prenatal testing.

The high incidence rate of Down syndrome is one of the major factors driving the non-invasive prenatal testing (NIDP) market with an increase in the average age of the mother, which has raised concerns about to the safety of the growth of the fetus. Down syndrome is a chromosomal disease that occurs. when an error in cell division results in an extra chromosome 21 and can affect the cognitive ability and physical growth of the fetus.

NIPT screening tests do not harm mother or baby, pose no risk of miscarriage because they are non-invasive and can detect over 99% of cases of Down syndrome. According to the National Down Syndrome Society and the Centers for Disease Control and Prevention, in the United States, 1 in 700 babies are born with Down syndrome and 80% of children with Down syndrome are born to older mothers.

The increased risk of having babies with Down syndrome in older women is driving the market for non-invasive prenatal testing.

The non-invasive prenatal testing market is regulated by several regulations governed by several international and national agencies. CLIA certification).

The manufacturer must obtain pre-market notification 510 (k) for in vitro diagnostic testing. LDT and CLIA certifications are based on the number of tests performed during clinical trials.

For example: For trisomy 21 (Down syndrome), there is an incidence of 1/1000. Given a goal of 100 positive results, at least 100,000 samples should be tested to meet the requirements of a 510k.

A 510k pre-market notification demonstrates that the new product is at least as safe and effective as another legally marketed device. It is mandatory for manufacturers to register a pre-market notification before a new product can be certified as commercially fit.

The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, United Kingdom and United States.
Read the full report:

About Reportlinker
ReportLinker is an award winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.


CONTACT: Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001

Comments are closed.